Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,174.37 -61.89 (-0.09%) CMC Crypto 200
1,372.74 -45.13 (-3.18%)
Sandoz Group AG (SDZNY)
| Previous close | 36.09 |
| Open | 36.00 |
| Bid | 35.75 x 45900 |
| Ask | 35.80 x 27000 |
| Day's range | 35.95 - 36.06 |
| 52-week range | 25.71 - 36.18 |
| Volume | |
| Avg. volume | 106,790 |
| Market cap | 15.456B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 199.72 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.50 (1.39%) |
| Ex-dividend date | 03 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
Improving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio
Michel Robidoux Michel Robidoux PrSandoz® Lisdexamfetamine, one of first generic equivalents of Vyvanse*, available on Canadian marketApproved for all indications of reference medicine: Attention Deficit Hyperactivity Disorder and Binge Eating Disorder in adultsPrSandoz® Amoxicillin, PrSandoz® Desvenlafaxine and PrSandoz® Riociguat also joined Sandoz Canada’s generics portfolio this spring BOUCHERVILLE, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada announced today the launch of PrSando
- GlobeNewswire
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in gener
- GlobeNewswire
Sandoz reports first quarter 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)Biosimilar business growing 21% in constant currencies All regions contributing to growthAcquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the f
